Study: NCT00158782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034
Description: GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-alpha (PDGFR-alpha), PDGFR-beta, and c-Kit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034
Description: GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-alpha (PDGFR-alpha), PDGFR-beta, and c-Kit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034
Description: GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-alpha (PDGFR-alpha), PDGFR-beta, and c-Kit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034
Description: GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-alpha (PDGFR-alpha), PDGFR-beta, and c-Kit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034
Description: GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-alpha (PDGFR-alpha), PDGFR-beta, and c-Kit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034
Description: GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-alpha (PDGFR-alpha), PDGFR-beta, and c-Kit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034
Description: GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-alpha (PDGFR-alpha), PDGFR-beta, and c-Kit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034
Description: GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-alpha (PDGFR-alpha), PDGFR-beta, and c-Kit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Lapatinib is an oral, reversible, tyrosine kinase inhibitor of both epidermal growth factor receptor-1 (ErbB1) and ErbB2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Lapatinib is an oral, reversible, tyrosine kinase inhibitor of both epidermal growth factor receptor-1 (ErbB1) and ErbB2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Lapatinib is an oral, reversible, tyrosine kinase inhibitor of both epidermal growth factor receptor-1 (ErbB1) and ErbB2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Lapatinib is an oral, reversible, tyrosine kinase inhibitor of both epidermal growth factor receptor-1 (ErbB1) and ErbB2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Lapatinib is an oral, reversible, tyrosine kinase inhibitor of both epidermal growth factor receptor-1 (ErbB1) and ErbB2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Lapatinib is an oral, reversible, tyrosine kinase inhibitor of both epidermal growth factor receptor-1 (ErbB1) and ErbB2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Lapatinib is an oral, reversible, tyrosine kinase inhibitor of both epidermal growth factor receptor-1 (ErbB1) and ErbB2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Lapatinib is an oral, reversible, tyrosine kinase inhibitor of both epidermal growth factor receptor-1 (ErbB1) and ErbB2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Lapatinib is an oral, reversible, tyrosine kinase inhibitor of both epidermal growth factor receptor-1 (ErbB1) and ErbB2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Lapatinib is an oral, reversible, tyrosine kinase inhibitor of both epidermal growth factor receptor-1 (ErbB1) and ErbB2.